ANNX - Annexon Inc logo

Annexon Inc

ANNX

Annexon Inc is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for inflammatory diseases. Its key products include monoclonal antibodies and small molecules in various clinical trial phases for conditions like Guillain-Barré syndrome and Huntington's disease.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago →$206today

Score Overview

1 Year
Score—
Net Growth4.94%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score—
Net Growth-53.75%
Net Trend40%
Net Income Consistency—
Rev Growth—
Rev TrendNever
Revenue Consistency—
All Time
Score—
Net Growth-213.13%
Net Trend33%
Net Income Consistency
Rev Growth—
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Annexon Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ANNX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 3.81—
1 Year2025-10-22
$ 3.0027.00%
5 Years2021-10-22
$ 18.49-79.39%
All Time2020-07-24
$ 17.76-78.55%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 196M$ 225M
2025$ 0.00-$ 206M$ 238M
2024$ 0.00-$ 138M$ 312M
2023$ 0.00-$ 134M$ 259M
2022$ 0.00-$ 138M$ 242M
2021$ 0.00-$ 127M$ 242M
IPO2020$ 0.00-$ 62M$ 351M
ANNX - Annexon Inc logo

Annexon Inc fundamental performance

Across Annexon Inc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 62M to -$ 206M. Revenue increased in 0% of the years measured; net income in 33%.

Membership

Explore ANNX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,118 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies